Forest’s Combunox Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's combination pain therapy Combunox was approved by FDA, the company said Nov. 26
Forest's combination pain therapy Combunox was approved by FDA, the company said Nov. 26. Combunox (oxycodone 5 mg/ibuprofen 400 mg) tablets are approved for the short-term management of acute moderate to severe pain. Forest has U.S. marketing rights to Combunox under a licensing agreement with BTG (1 (Also see "Forest Bites At Stroke Clot Dissolver; Desmoteplase Could Have Nine-Hour Treatment Window" - Pink Sheet, 6 Jul, 2004.)). The company expects to launch the product early in 2005. |